Extracellular vesicles in cancer nanomedicine
Abstract
To date, a lot of nanotechnological optitions are available for targeted drug delivery. Extracellular vesicles (EVs) are membrane structures that cells use for storage, transport, communication, and signaling. Recent research has focused on EVs as natural nanoparticles for drug delivery. This review sheds light on the application of EVs in cancer therapy, such as targeted chemotherapy, gene therapy, and vaccine development. Aspects of biogenesis, isolation, targeting, and loading of EVs are discussed in detail.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TDEs could be devised as natural drug carriers with higher cancer cell targeting and therapeutic efficacy, low toxicity, and permeability.
“Therefore, TDEs could be devised as natural drug carriers with higher cancer cell targeting and therapeutic efficacy, low toxicity, and permeability [41].”
From The Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System (2022) · cites this paper as [41]
The citation lists haven’t been fetched yet
References 148 · Cited by 97
- Authors
- Tarasov, V. V., Svistunov, A. A., Chubarev, V. N., Dostdar, S. A., Sokolov, A. V., Brzecka, A., Sukocheva, O., Neganova, M. E., Klochkov, S. G., Somasundaram, S. G., Kirkland, C. E., & Aliev, G.
- Affiliations
- Sechenov University (RU)
- University of Wrocław (PL)
- Flinders University (AU)
- Institute of Physiologically Active Compounds (RU)
- Salem University (US)
- Russian Academy of Sciences (RU)
- Corresponding author
- Aliev, Gjumrakch
- ORCID
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 69
- Pages
- 212-225
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2967761711
- Cited by
- 97
- References
- 148
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 16 · 2023: 19 · 2022: 23 · 2021: 16 · 2020: 15
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Cancer Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Russian Academic Excellence project "5-100”
- Ministry of Science and High Education of the Russian Federation
- RAS Program "Fundamental Research for Biomedical Technologies’
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- extracellular vesicles, cancer nanomedicine, targeted drug delivery, cancer therapy, chemotherapy, gene therapy, cancer vaccines, EV biogenesis, EV isolation
- MeSH terms
- Extracellular Vesicles, Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, Nanomedicine, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
